A Two-Part, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of GXV-001 in Healthy Volunteers
Latest Information Update: 13 Jul 2023
At a glance
- Drugs GXV 001 (Primary)
- Indications Angelman syndrome; Fragile X syndrome; Rett syndrome
- Focus Adverse reactions
- Sponsors GEXVal
Most Recent Events
- 13 Jul 2023 New trial record
- 11 Jul 2023 Status changed from recruiting to completed according to a GEXVal media release.
- 15 Feb 2023 According to a GEXVal media release, this study was approved by the Safety Review Committee (SRC) after completing the single-dose study. The first dose of the first patient has been completed.